Navigation Links
Green neighborhoods may reduce childhood obesity
Date:10/27/2008

San Diego, October 28, 2008 Childhood obesity can lead to type 2 diabetes, asthma, hypertension, sleep apnea and emotional distress. Obese children and youth are likely to be obese as adults, experience more cardiovascular disease, high blood pressure and stroke and incur higher healthcare costs. In an article published in the December 2008 issue of the American Journal of Preventive Medicine, researchers report that children living in inner city neighborhoods with higher "greenness" experienced lower weight gains compared to those in areas with less green space.

Researchers from the University of Washington, Indiana University-Purdue University and Indiana University School of Medicine followed more than 3800 children, predominantly African-American and poor, aged 3-16 over a two-year period. Using satellite imaging data to measure vegetation coverage, the investigators found that higher greenness was significantly associated with lower body mass index (BMI) changes in those children. In previous studies of adults, residential density tended to predict physical activity levels, with highly urban environments leading to more walking, less driving and lower BMI. The current study did not find this correlation for children.

Children and youth in urban environments may be active in a wider variety of open spaces (e.g., yards, parks, vacant lots) and less likely to constrain activity to streets and sidewalks. Greenness might indicate proximity to parks, playfields or other open spaces that promote either physical activity or increased time spent outdoors in active play.

Writing in the article, Janice F. Bell, PhD, MPH, Assistant Professor in the department of Health Services at the School of Public Health and Community Medicine, University of Washington, Seattle, and co-investigators state, "This study's findings align with previous research linking exposure to green landscapes with health improvements. Among adults, greenness is
'/>"/>

Contact: AJPM Editorial Office
eAJPM@ucsd.edu
858-457-7292
Elsevier Health Sciences
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Neighborhood greenness has long term positive impact on kids health
2. Green Valley Spa Now Offers hCG Weight Loss Therapy
3. Heifer International: The Greener Good for Holiday Giving
4. MBL scientist Osamu Shimomura wins Nobel Prize for discovery of green fluorescent protein
5. Walgreens Pays U.S. $9.9 Million to Settle Medicaid Prescription Drug Allegations
6. Modular Building Systems International (MBSI) Supplies Buildings For First Platinum Certified Green Modular School In The U.S.
7. Longs Drug Stores Confirms Receipt of Expression of Interest from Walgreens
8. Greenway Medical Technologies Growth Continues with Significant Fiscal Year 2008 Gains
9. Luxury Resort Operates Seasonal Green Market for 2,300 Staff
10. ChromaDex Licenses Green Chemistry Technology to Manufacture a New Class of Super Fruit Compounds
11. Ron Greenspan DDS Creates Plan to Eliminate the Barriers to Orthodontic Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:National Ergonomics Expo Sees Immediate 93% Exhibit Space Renewal for 2010; Equipois, Herman Miller, Neutral Posture, REDpoint International Win 2009 Attendees' Choice New Product Awards 2Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 3Baxa Corporation Releases IntelliFlowRx 28TM 29 Upgrades 49198 1Baxa Corporation Releases IntelliFlowRx 28TM 29 Upgrades 49198 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 1Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 3Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 4Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 5Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 6Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 7Stroke Damage Is Less in Rats Given Opioids 49194 1